The National Institute on Aging was not otherwise involved in the design and conduct of the study, or in the analysis of data or preparation of the manuscript'. Study funding quote: 'grant UO1‐AG10483 from the National Institute on Aging. Main study outcome: change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS‐cog) and change in the Clinical Dementia Rating (CDR)ĭropouts: 67 intervention, 40 control (discontinued treatment but included in main analyses)Īvailable outcomes: mortality, measures of cognition, baseline & change in plasma DHA, adverse events

Dose: +DHA 1.02 g/d.Ĭontrol: 2 × 1 g placebo capsules per day (made up of corn or soy oil)Ĭompliance: measured by pill counts at every visit Intervention: 2 × 1 g algal‐derived DHA capsules (Neuromins) per day for a total daily dose of 2 g, each capsule contain 45% to 55% of DHA and does not contain EPA (950 mg soft‐gel capsules which contain approximately 510 mg DHA). Medications taken by some, but less than 20% of the control group: none Medications taken by 20%‐49% of those in the control group: none Medications taken by at least 50% of those in the control group: cholinesterase inhibitor, memantine

Smokers: 24.4% intervention, 21.9% control Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control Individuals with mild to moderate Alzheimer's disease RCT, parallel, (n‐3 DHA vs n‐6 LA), 18 months Alzheimer's Disease Cooperative Study (ADCS)

4.34 file juicer